Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals, Inc. reports developments across a diversified pharmaceutical business built around Affordable Medicines, Specialty and AvKARE. Its updates commonly cover U.S. launches of complex generics, injectables, biosimilars and other affordable medicines, including respiratory inhalation and ophthalmic products, as well as branded specialty treatments in neurology and endocrinology.
News about AMRX also includes clinical and regulatory disclosures for products such as CREXONT for Parkinson’s disease, financial results, capital-structure updates, material agreements and governance matters. AvKARE-related updates center on distribution of pharmaceuticals and medical products to U.S. federal, retail and institutional customers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Amneal Pharmaceuticals (NYSE: AMRX) will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023. Co-CEO Chirag Patel and CFO Tasos Konidaris will represent the company. Mr. Patel will also host a fireside chat at 11:45 AM ET. Investors can access a live webcast from the Investor Relations section of Amneal's website, with a replay available for 90 days post-event.
Amneal is based in Bridgewater, NJ, and focuses on developing, manufacturing, and distributing around 270 generic and specialty pharmaceuticals in the U.S. The company is expanding its Generics segment with complex products and has a robust portfolio in Specialty pharmaceuticals aimed at addressing unmet medical needs.
Amneal Pharmaceuticals (NYSE: AMRX) reported preliminary financial results for Q1 2023, expecting net revenues of $550 million to $560 million, reflecting a 12% increase compared to Q1 2022. Loss before income taxes improved to between $10 million and $0, marking a 50% enhancement year-over-year. Adjusted EBITDA is anticipated to be between $115 million and $120 million, up 18% from the previous year. As of March 31, 2023, long-term debt stood at $2.692 billion, with cash reserves of $151 million, lowering net debt to $2.541 billion. The company reaffirmed its full-year guidance, maintaining projected net revenues of $2.25 billion to $2.35 billion.